Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Angiogenic factors and fetal Doppler for predicting adverse pregnancy outcome in early-onset small fetuses with and without pre-eclampsia

  • Casellas de Miguel, Alba
  • Dalmau Artal, Marta
  • Díaz Fernández, Patricia
  • Temprado Piqueras, Joaquin
  • Duaso, M.
  • Ampurdanés Noró, Queralt
  • Armengol, T.
  • Lizarraga, Z.
  • Bonacina, Erika
  • Armengol Alsina, Mireia
  • Roldán Alarcón, Eva
  • San José Moya, Marta
  • Maiz, Nerea
  • Mendoza, Manel
Doppler; Angiogenic factors; Fetal growth restriction, Doppler; Factores angiogénicos; Restricción del crecimiento fetal, Doppler; Factors angiogènics; Restricció del creixement fetal, Objectives To assess the predictive performance of angiogenic factors and fetal Doppler, alone and in combination, for composite adverse perinatal outcome (CAPO) in early-onset small-for-gestational age (SGA) and fetal growth restriction (FGR), in cases both with and without pre-eclampsia (PE), in order to evaluate the ability of these markers to predict adverse outcomes beyond their established association with PE and to better delineate the specific contribution of PE to their predictive value. Methods This was a retrospective observational study conducted at Vall d'Hebron University Hospital, Barcelona, Spain, between January 2016 and January 2022. The study population included singleton pregnancies with an estimated fetal weight < 10th percentile, diagnosed with fetal smallness between 20 + 0 and 31 + 6 weeks' gestation, with fetal Doppler ultrasound data and available angiogenic factor measurements obtained at diagnosis. Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) were measured at initial assessment. CAPO was defined as the presence of at least one of the following: 5-min Apgar score < 7; umbilical cord arterial pH < 7.0; admission to the neonatal intensive care unit for > 48 h; stillbirth; neonatal death; respiratory distress syndrome; bronchopulmonary dysplasia; neonatal sepsis; necrotizing enterocolitis; Grade-III–IV retinopathy of prematurity; Grade-III–IV intraventricular hemorrhage; or periventricular leukomalacia. Predictive performance for CAPO and subsequent PE was assessed using receiver-operating-characteristics (ROC)-curve analysis and area under the ROC curve (AUC) comparisons for fetal Doppler and angiogenic factors, alone and combined, within logistic regression models. Sensitivity, false-positive rate, positive predictive value and negative predictive value were calculated. All analyses were stratified according to PE development at any time before delivery. Results Overall, 469 women with an early-onset small fetus were included. PE was present at diagnosis in 74/469 (15.8%) cases and developed later in 83 (17.7%) cases. CAPO occurred in 46.5% of cases. In the overall cohort, PlGF combined with fetal Doppler findings showed the highest predictive performance for CAPO (AUC, 0.866 (95% CI, 0.833–0.899)), outperforming fetal Doppler alone. Notably, the performance of the combined model was not significantly different from PlGF alone (AUC, 0.862 (95% CI, 0.828–0.895); P = 0.621). These findings were consistent in pregnancies without PE, in which PlGF remained the best-performing single predictor of CAPO (AUC, 0.797 (95% CI, 0.740–0.854)). In pregnancies with PE at any time, the best-performing single predictor was the sFlt-1/PlGF ratio (AUC, 0.802 (95% CI, 0.728–0.876)). For the prediction of subsequent PE after enrolment, the sFlt-1/PlGF ratio alone (AUC, 0.861 (95% CI, 0.821–0.901)) and in combination with fetal Doppler (AUC, 0.862 (95% CI, 0.822–0.902)) achieved the highest predictive performance. Combining fetal Doppler findings with angiogenic factors reduced false-positive rates, but did not improve sensitivity. Conclusion This study confirmed the robust predictive performance of PlGF and the sFlt-1/PlGF ratio for identifying CAPO and PE in early-onset SGA/FGR. The predictive value of PlGF and fetal Doppler remained consistent irrespective of PE status, while the sFlt-1/PlGF ratio showed reduced predictive accuracy in non-PE pregnancies, but still outperformed Doppler. These findings support the integration of angiogenic factors into the clinical assessment of early-onset SGA/FGR, for both cases with and those without PE. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., E.B. has been funded by Instituto de Salud Carlos III (ISCIII) through the project ‘JR23/00004’ and cofunded by the European Union. M.A.-A. has been funded by ISCIII through the project ‘CM23/00017’ and cofunded by the European Union. M.M. and E.B. received lecture fees from Roche Diagnostics.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cost–benefit analysis of first-trimester pre-eclampsia screening: comparison of multivariable Gaussian algorithm with and without placental growth factor, Análisis de costo-beneficio de la detección de la preeclampsia en el primer trimestre: comparación del algoritmo multivariable de Gauss con y sin factor de crecimiento placentario

  • Armengol Alsina, Mireia
  • Dalmau Artal, Marta
  • Casellas de Miguel, Alba
  • Roldán Alarcón, Eva
  • Kumari , Neeti
  • Arias García, Andrea
  • Bonacina, Erika
  • del Barco Martínez, Ester
  • Ferrer Costa, Roser
  • Maiz, Nerea
  • Mendoza, Manel
First trimester; Pre‐eclampsia; Screening, Primer trimestre; Preeclampsia; Cribado, Primer trimestre; Preeclàmpsia; Cribratge, Objective Pre-eclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Early identification of high-risk pregnancies in the first trimester allows preventive treatment with low-dose aspirin. This study aimed to evaluate whether multivariable Gaussian algorithm-based PE screening strategies, with and without placental growth factor (PlGF), are cost beneficial compared with no screening. Methods The cost–benefit analysis estimated the total healthcare savings for the two screening strategies compared with no screening, considering both the costs associated with implementing the screening and the savings derived from the number of cases of PE and preterm infants prevented. The analysis was based on real-world data from Catalan maternity centers applied to a cohort of 56 344 pregnancies (annual birth rate in 2023). Univariable sensitivity and best- and worst-case scenario analyses were also conducted. Results Both screening strategies resulted in cost savings compared with no screening. The Gaussian algorithm without PlGF yielded greater healthcare savings (€3.38 million) than did the Gaussian algorithm with PlGF (€3.29 million). However, the addition of PlGF provided greater clinical benefit, preventing a higher number of PE cases. Sensitivity analysis identified PE incidence and preterm birth rates as the primary cost drivers. For the PlGF strategy to be cost beneficial, the PlGF reagent cost per unit should not exceed €4.31. Conclusions Although the Gaussian algorithm without PlGF demonstrated the highest cost savings compared with no screening, incorporating PlGF further improved PE prevention, supporting its broader adoption. A PlGF reagent cost per unit below €4.31 may make this strategy cost-beneficial, enhancing its clinical implementation. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., Objetivo La preeclampsia (PE) es una de las principales causas de morbilidad y mortalidad materna y neonatal en todo el mundo. La identificación precoz de los embarazos de alto riesgo en el primer trimestre permite el tratamiento preventivo con dosis bajas de aspirina. El objetivo de este estudio fue evaluar si las estrategias de detección de la PE basadas en algoritmos multivariables de Gauss, con y sin factor de crecimiento placentario (FCPl), son rentables en comparación con la ausencia de pruebas de detección. Métodos El análisis de costo-beneficio estimó el ahorro sanitario total de las dos estrategias de detección en comparación con la ausencia de pruebas de detección, para lo cuál se consideraron tanto los costos asociados a las pruebas de detección como el ahorro derivado de la prevención del número de casos de PE y de recién nacidos prematuros. El análisis se basó en datos reales de centros de maternidad catalanes aplicados a una cohorte de 56 344 embarazos (tasa de natalidad anual en 2023). También se realizaron análisis de sensibilidad univariable y análisis de escenarios de mejor y peor caso. Resultados Ambas estrategias de detección supusieron un ahorro de costos en comparación con la ausencia de pruebas de detección. El algoritmo de Gauss sin FCPl produjo un mayor ahorro sanitario (3,38 millones de euros) que el algoritmo de Gauss con FCPl (3,29 millones de euros). Sin embargo, la adición del FCPl proporcionó un mayor beneficio clínico, ya que evitó un mayor número de casos de PE. El análisis de sensibilidad identificó la frecuencia de PE y las tasas de nacimientos prematuros como los principales generadores de costos. Para que la estrategia con FCPl sea rentable, el costo por unidad del reactivo FCPl no debe superar los 4,31 euros. Conclusiones Aunque el algoritmo de Gauss sin FCPl demostró un mayor ahorro de costos en comparación con la ausencia de pruebas de detección, la incorporación del FCPl mejoró aún más la prevención de la PE, lo que apoya su adopción más amplia. Un coste unitario del reactivo FCPl inferior a 4,31 euros puede hacer que esta estrategia sea rentable, lo que favorecería su aplicación clínica., We thank all physicians and participants who agreed to take part in the original studies, and Roche Diagnostics for providing the reagents. We also thank Ciro Salvi for preparing the figures for this paper. E.B. was funded by Instituto de Salud Carlos III (ISCIII) through the project “JR23/00004” and co-funded by the European Union. M.A-A. was funded by Instituto de Salud Carlos III (ISCIII) through the project “CM23/00017” and co-funded by the European Union. M.M. and E.B. received lecture fees from Roche Diagnostics.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Angiogenic factors and fetal Doppler for predicting adverse pregnancy outcome in early-onset small fetuses with and without pre-eclampsia

  • Casellas de Miguel, Alba
  • Dalmau Artal, Marta
  • Díaz Fernández, Patricia
  • Temprado Piqueras, Joaquin
  • Duaso, M.
  • Ampurdanés Noró, Queralt
  • Armengol, T.
  • Lizarraga, Z.
  • Bonacina, Erika
  • Armengol Alsina, Mireia
  • Roldán Alarcón, Eva
  • San José Moya, Marta
  • Maiz, Nerea
  • Mendoza, Manel
Doppler; Angiogenic factors; Fetal growth restriction, Doppler; Factores angiogénicos; Restricción del crecimiento fetal, Doppler; Factors angiogènics; Restricció del creixement fetal, Objectives To assess the predictive performance of angiogenic factors and fetal Doppler, alone and in combination, for composite adverse perinatal outcome (CAPO) in early-onset small-for-gestational age (SGA) and fetal growth restriction (FGR), in cases both with and without pre-eclampsia (PE), in order to evaluate the ability of these markers to predict adverse outcomes beyond their established association with PE and to better delineate the specific contribution of PE to their predictive value. Methods This was a retrospective observational study conducted at Vall d'Hebron University Hospital, Barcelona, Spain, between January 2016 and January 2022. The study population included singleton pregnancies with an estimated fetal weight < 10th percentile, diagnosed with fetal smallness between 20 + 0 and 31 + 6 weeks' gestation, with fetal Doppler ultrasound data and available angiogenic factor measurements obtained at diagnosis. Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) were measured at initial assessment. CAPO was defined as the presence of at least one of the following: 5-min Apgar score < 7; umbilical cord arterial pH < 7.0; admission to the neonatal intensive care unit for > 48 h; stillbirth; neonatal death; respiratory distress syndrome; bronchopulmonary dysplasia; neonatal sepsis; necrotizing enterocolitis; Grade-III–IV retinopathy of prematurity; Grade-III–IV intraventricular hemorrhage; or periventricular leukomalacia. Predictive performance for CAPO and subsequent PE was assessed using receiver-operating-characteristics (ROC)-curve analysis and area under the ROC curve (AUC) comparisons for fetal Doppler and angiogenic factors, alone and combined, within logistic regression models. Sensitivity, false-positive rate, positive predictive value and negative predictive value were calculated. All analyses were stratified according to PE development at any time before delivery. Results Overall, 469 women with an early-onset small fetus were included. PE was present at diagnosis in 74/469 (15.8%) cases and developed later in 83 (17.7%) cases. CAPO occurred in 46.5% of cases. In the overall cohort, PlGF combined with fetal Doppler findings showed the highest predictive performance for CAPO (AUC, 0.866 (95% CI, 0.833–0.899)), outperforming fetal Doppler alone. Notably, the performance of the combined model was not significantly different from PlGF alone (AUC, 0.862 (95% CI, 0.828–0.895); P = 0.621). These findings were consistent in pregnancies without PE, in which PlGF remained the best-performing single predictor of CAPO (AUC, 0.797 (95% CI, 0.740–0.854)). In pregnancies with PE at any time, the best-performing single predictor was the sFlt-1/PlGF ratio (AUC, 0.802 (95% CI, 0.728–0.876)). For the prediction of subsequent PE after enrolment, the sFlt-1/PlGF ratio alone (AUC, 0.861 (95% CI, 0.821–0.901)) and in combination with fetal Doppler (AUC, 0.862 (95% CI, 0.822–0.902)) achieved the highest predictive performance. Combining fetal Doppler findings with angiogenic factors reduced false-positive rates, but did not improve sensitivity. Conclusion This study confirmed the robust predictive performance of PlGF and the sFlt-1/PlGF ratio for identifying CAPO and PE in early-onset SGA/FGR. The predictive value of PlGF and fetal Doppler remained consistent irrespective of PE status, while the sFlt-1/PlGF ratio showed reduced predictive accuracy in non-PE pregnancies, but still outperformed Doppler. These findings support the integration of angiogenic factors into the clinical assessment of early-onset SGA/FGR, for both cases with and those without PE. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., E.B. has been funded by Instituto de Salud Carlos III (ISCIII) through the project ‘JR23/00004’ and cofunded by the European Union. M.A.-A. has been funded by ISCIII through the project ‘CM23/00017’ and cofunded by the European Union. M.M. and E.B. received lecture fees from Roche Diagnostics.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Cost–benefit analysis of first-trimester pre-eclampsia screening: comparison of multivariable Gaussian algorithm with and without placental growth factor, Análisis de costo-beneficio de la detección de la preeclampsia en el primer trimestre: comparación del algoritmo multivariable de Gauss con y sin factor de crecimiento placentario

  • Armengol Alsina, Mireia
  • Dalmau Artal, Marta
  • Casellas de Miguel, Alba
  • Roldán Alarcón, Eva
  • Kumari , Neeti
  • Arias García, Andrea
  • Bonacina, Erika
  • del Barco Martínez, Ester
  • Ferrer Costa, Roser
  • Maiz, Nerea
  • Mendoza, Manel
First trimester; Pre‐eclampsia; Screening, Primer trimestre; Preeclampsia; Cribado, Primer trimestre; Preeclàmpsia; Cribratge, Objective Pre-eclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Early identification of high-risk pregnancies in the first trimester allows preventive treatment with low-dose aspirin. This study aimed to evaluate whether multivariable Gaussian algorithm-based PE screening strategies, with and without placental growth factor (PlGF), are cost beneficial compared with no screening. Methods The cost–benefit analysis estimated the total healthcare savings for the two screening strategies compared with no screening, considering both the costs associated with implementing the screening and the savings derived from the number of cases of PE and preterm infants prevented. The analysis was based on real-world data from Catalan maternity centers applied to a cohort of 56 344 pregnancies (annual birth rate in 2023). Univariable sensitivity and best- and worst-case scenario analyses were also conducted. Results Both screening strategies resulted in cost savings compared with no screening. The Gaussian algorithm without PlGF yielded greater healthcare savings (€3.38 million) than did the Gaussian algorithm with PlGF (€3.29 million). However, the addition of PlGF provided greater clinical benefit, preventing a higher number of PE cases. Sensitivity analysis identified PE incidence and preterm birth rates as the primary cost drivers. For the PlGF strategy to be cost beneficial, the PlGF reagent cost per unit should not exceed €4.31. Conclusions Although the Gaussian algorithm without PlGF demonstrated the highest cost savings compared with no screening, incorporating PlGF further improved PE prevention, supporting its broader adoption. A PlGF reagent cost per unit below €4.31 may make this strategy cost-beneficial, enhancing its clinical implementation. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., Objetivo La preeclampsia (PE) es una de las principales causas de morbilidad y mortalidad materna y neonatal en todo el mundo. La identificación precoz de los embarazos de alto riesgo en el primer trimestre permite el tratamiento preventivo con dosis bajas de aspirina. El objetivo de este estudio fue evaluar si las estrategias de detección de la PE basadas en algoritmos multivariables de Gauss, con y sin factor de crecimiento placentario (FCPl), son rentables en comparación con la ausencia de pruebas de detección. Métodos El análisis de costo-beneficio estimó el ahorro sanitario total de las dos estrategias de detección en comparación con la ausencia de pruebas de detección, para lo cuál se consideraron tanto los costos asociados a las pruebas de detección como el ahorro derivado de la prevención del número de casos de PE y de recién nacidos prematuros. El análisis se basó en datos reales de centros de maternidad catalanes aplicados a una cohorte de 56 344 embarazos (tasa de natalidad anual en 2023). También se realizaron análisis de sensibilidad univariable y análisis de escenarios de mejor y peor caso. Resultados Ambas estrategias de detección supusieron un ahorro de costos en comparación con la ausencia de pruebas de detección. El algoritmo de Gauss sin FCPl produjo un mayor ahorro sanitario (3,38 millones de euros) que el algoritmo de Gauss con FCPl (3,29 millones de euros). Sin embargo, la adición del FCPl proporcionó un mayor beneficio clínico, ya que evitó un mayor número de casos de PE. El análisis de sensibilidad identificó la frecuencia de PE y las tasas de nacimientos prematuros como los principales generadores de costos. Para que la estrategia con FCPl sea rentable, el costo por unidad del reactivo FCPl no debe superar los 4,31 euros. Conclusiones Aunque el algoritmo de Gauss sin FCPl demostró un mayor ahorro de costos en comparación con la ausencia de pruebas de detección, la incorporación del FCPl mejoró aún más la prevención de la PE, lo que apoya su adopción más amplia. Un coste unitario del reactivo FCPl inferior a 4,31 euros puede hacer que esta estrategia sea rentable, lo que favorecería su aplicación clínica., We thank all physicians and participants who agreed to take part in the original studies, and Roche Diagnostics for providing the reagents. We also thank Ciro Salvi for preparing the figures for this paper. E.B. was funded by Instituto de Salud Carlos III (ISCIII) through the project “JR23/00004” and co-funded by the European Union. M.A-A. was funded by Instituto de Salud Carlos III (ISCIII) through the project “CM23/00017” and co-funded by the European Union. M.M. and E.B. received lecture fees from Roche Diagnostics.